Compare DexCom, Inc. (DXCM) vs Koninklijke Philips NV (PHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Koninklijke Philips NV — how do they compare? DexCom, Inc. trades at $84.38 (market cap $31.86B), while Koninklijke Philips NV trades at $24.51 (market cap $23.52B). The key difference: DexCom, Inc. is the larger of the two by market cap, and Koninklijke Philips NV pays a 4.17% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Koninklijke Philips NV for 84 Days on average.
| DXCM | PHG | |
|---|---|---|
Market Cap | $31.86B | $23.52B |
Volume | 3,607,070 | 1,635,069 |
Sector | Health | Health |
52-Week High | $92.34 | $32.91 |
52-Week Low | $54.84 | $23.81 |
Typical Hold Time | 62 Days | 84 Days |
Enterprise Value | $31.32B | $29.87B |
Dividend Yield | — | 4.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal but strong fundamentals. Revenue grew to $4.66B in 2025, with net income of $836.3M and a 17.93% margin. The stock has a P/E of 33.32 and P/S of 6.74. Recent news highlights growth in CGM adoption for Type 2 diabetes. Analyst consensus is bullish with an average price target of $95.07, supported by 42 buy ratings.
Outlook remains positive due to earnings beats and market expansion, but risks include competition and reimbursement challenges. The stock offers growth potential, yet investors should monitor execution against high valuations and technical resistance near $85.
PHG trades at $24.09, down 0.25% on the day, with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with net income turning positive to $895M in 2025 after previous losses, supported by strong operational cash flow of $1.17B. Recent news highlights product innovations including new CT systems and AI healthcare tools, while institutional investors like Bank of America and Arrowstreet Capital have increased positions.
PHG presents a mixed outlook with solid profitability recovery but technical weakness. The stock offers value at reasonable valuations (P/E 18.84, P/S 1.18) and analyst consensus leans Hold (63.64%). Key risks include cybersecurity threats (Reuters, 2026-08-13) and debt levels, while opportunities lie in healthcare technology expansion and Exor's potential increased stake to 22% (Reuters, 2026-08-11).
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →
